Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer

Autophagy is a complex process of autodigestion in conditions of cellular stress, and it might play an important role in the pathophysiology during carcinogenesis. We hypothesize that genetic variants of the autophagy pathway may influence clinical outcomes in prostate cancer patients. We genotyped 40 tagging single-nucleotide polymorphisms (SNPs) from 7 core autophagy pathway genes in 458 localized prostate cancer patients. Multivariate Cox regression was performed to evaluate the independent association of each SNP with disease progression. Positive findings were then replicated in an independent cohort of 504 advanced prostate cancer patients. After adjusting for known clinicopathologic factors, the association between ATG16L1 rs78835907 and recurrence in localized disease [hazard ratio (HR) 0.70, 95% confidence interval (CI) 0.54–0.90, P = 0.006] was replicated in more advanced disease (HR 0.78, 95% CI 0.64–0.95, P = 0.014). Additional integrated in silico analysis suggests that rs78835907 tends to affect ATG16L1 expression, which in turn is correlated with tumor aggressiveness and patient prognosis. In conclusion, genetic variants of the autophagy pathway contribute to the variable outcomes in prostate cancer, and discovery of these novel biomarkers might help stratify patients according to their risk of disease progression.

[1]  Hong-Zin Lee,et al.  Clinical significance of runt‐related transcription factor 1 polymorphism in prostate cancer , 2011, BJU international.

[2]  S. Mendrinos,et al.  Autophagy proteins in prostate cancer: relation with anaerobic metabolism and Gleason score. , 2014, Urologic oncology.

[3]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[4]  Y. Pu,et al.  Polymorphisms inside MicroRNAs and MicroRNA Target Sites Predict Clinical Outcomes in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy , 2010, Clinical Cancer Research.

[5]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[6]  Hong-Zin Lee,et al.  Prognostic Significance of Prostate Cancer Susceptibility Variants on Prostate-Specific Antigen Recurrence after Radical Prostatectomy , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[7]  P. Kantoff,et al.  Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Kiemeney,et al.  The effect of the ATG16L1 Thr300Ala polymorphism on susceptibility and outcome of patients with epithelial cell-derived thyroid carcinoma. , 2012, Endocrine-related cancer.

[9]  Hong-Zin Lee,et al.  Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[10]  C. Guillemette,et al.  Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer , 2014, International journal of cancer.

[11]  David Haussler,et al.  ENCODE Data in the UCSC Genome Browser: year 5 update , 2012, Nucleic Acids Res..

[12]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[13]  Robin Mathew,et al.  Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. , 2011, Current opinion in genetics & development.

[14]  Manolis Kellis,et al.  HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants , 2011, Nucleic Acids Res..

[15]  Chao-yuan Huang,et al.  Prognostic Significance of Cyclin D1 Polymorphisms on Prostate-Specific Antigen Recurrence After Radical Prostatectomy , 2013, Annals of Surgical Oncology.

[16]  A. Saftoiu,et al.  Determination of autophagy gene ATG16L1 polymorphism in human colorectal cancer. , 2014, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[17]  P. Matthias,et al.  Interplay between histone deacetylases and autophagy ‐ from cancer therapy to neurodegeneration , 2012, Immunology and cell biology.

[18]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[19]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[20]  J. Walczak,et al.  Prostate cancer: a practical approach to current management of recurrent disease. , 2007, Mayo Clinic proceedings.

[21]  P. Stattin,et al.  Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. , 2011, European urology.

[22]  E. Klein,et al.  Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. , 2007, European urology.

[23]  D. Rubinsztein,et al.  Regulation of mammalian autophagy in physiology and pathophysiology. , 2010, Physiological reviews.

[24]  S. Freedland,et al.  Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. , 2003, Urology.

[25]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.